This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Cassava (SAVA) Soars on Encouraging Alzheimer's Study Data
by Zacks Equity Research
Cassava's (SAVA) Alzheimer's disease candidate, simufilam, improved cognition and behavior scores following six months of treatment in an open-label clinical study.
Cassava Sciences' (SAVA) Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Cassava Sciences (SAVA).
Pacira (PCRX) Gets European Commission Approval for Exparel
by Zacks Equity Research
The EC approves Pacira's (PCRX) Exparel for treating post-operative pain in adults and as a field block for treating somatic post-operative pain from small- to medium-sized surgical wounds in adults.
OptiNose (OPTN) Looks Good: Stock Adds 6.2% in Session
by Zacks Equity Research
OptiNose (OPTN) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
Aerie (AERI) Gets Positive CHMP Opinion for Roclanda in EU
by Zacks Equity Research
Aerie (AERI) receives positive CHMP opinion for Roclanda for reduction of elevated intraocular pressure in adult patients.
Zoetis (ZTS) Librela Gets Marketing Authorization in Europe
by Zacks Equity Research
Zoetis (ZTS) gets marketing authorization for Librela, for monthly alleviation of osteoarthritis pain in dogs.
Jazz Pharma (JAZZ) Beats on Q3 Earnings, Ups Sales Guidance
by Zacks Equity Research
Jazz Pharmaceuticals (JAZZ) reports better-than-expected third-quarter 2020 earnings and revenues and ups its sales guidance for 2020.
What's in the Cards for Cassava (SAVA) This Earnings Season?
by Zacks Equity Research
Investors will be keen on updates from the recent study on its lead candidate, sumifilam, when Cassava (SAVA) reports Q3 results.
Moving Average Crossover Alert: Cassava Sciences
by Zacks Equity Research
Cassava Sciences is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
4 Small Drug Stocks to Look Out For Amid Coronavirus Uncertainty
by Kinjel Shah
There is uncertainty about the impact of the coronavirus pandemic on the Zacks Medical-Drugs industry. However, with demand trends expected to improve in the second half of 2020, SAVA, KMPH, NERV, ALDX may prove to be good additions to the portfolio.
Cassava Sciences' Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Cassava Sciences.
Healthcare ETFs, Stocks That Gained Double Digits Last Week
by Sweta Killa
The healthcare sector defied last week's market rout buoyed by the progress in the development of a coronavirus vaccine or treatment, and merger and acquisition news.
Cassava Sciences (SAVA) Jumps: Stock Rises 9.2%
by Zacks Equity Research
Cassava Sciences (SAVA) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.
Cassava Sciences (SAVA) in Focus: Stock Moves 8.5% Higher
by Zacks Equity Research
Cassava Sciences (SAVA) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.
Add Value to Your Portfolio With 5 High Earnings Yield Picks
by Rimmi Singhi
If other factors are constant while comparing stocks, the one with a higher earnings yield has the potential to provide comparatively greater returns.
Company News for Apr 24, 2020
by Zacks Equity Research
Companies In The News Are: LLY, SAVA, FLR, LYTS
What Lies Ahead for Cassava Sciences (SAVA) in Q4 Earnings?
by Zacks Equity Research
During the Q4 investors' call, Cassava Sciences (SAVA) is likely to provide an update on its lead candidate PT-125, which is being developed for the treatment of Alzheimer's disease.
The Zacks Analyst Blog Highlights: Agile Therapeutics, Air Industries, Dermira, Microbot Medical and Cassava Sciences
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Agile Therapeutics, Air Industries, Dermira, Microbot Medical and Cassava Sciences
Buy Multibagger Stocks as Odds of a Rally Are High in 2020
by Tirthankar Chakraborty
Multibagger stocks can make most of the bull run, courtesy of strong fundamentals and businesses that can multiply in a short span of time.
Zacks.com featured highlights include: Cassava Sciences, Rubicon Project, Talos Energy, Teekay Tankers and Karyopharm Therapeutics
by Zacks Equity Research
Zacks.com featured highlights include: Cassava Sciences, Rubicon Project, Talos Energy, Teekay Tankers and Karyopharm Therapeutics
5 Stocks With Recent Price Strength for Spectacular Returns
by Nalak Das
Investors target stocks that are witnessing a bullish run. Actually, stocks seeing price strength have a high chance of carrying the momentum forward.
Company News For Jan 3, 2020
by Zacks Equity Research
Companies in the news are: CMG, SAVA, RCON, IPHA
The Zacks Analyst Blog Highlights: EverQuote, Cassava Sciences, Fulgent Genetics, Teekay Tankers and Cue Biopharma
by Zacks Equity Research
The Zacks Analyst Blog Highlights: EverQuote, Cassava Sciences, Fulgent Genetics, Teekay Tankers and Cue Biopharma
5 Stocks to Soar in 2020 After Solid Gains in 2019
by Zacks Equity Research
U.S. stocks rallied to attained fresh all-time highs in 2019, as the momentum continued in 2020. Here are five stocks that are poised to grow.
Biotech Rally Sends Nasdaq to 9000: ETFs in Focus
by Sanghamitra Saha
Some biotech stocks have contributed materially to the Nasdaq's 1000-point gain since Aug 27, 2018 and helped it notch a record 9,000 on Dec 26.